These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1698 related articles for article (PubMed ID: 33294831)

  • 1. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived thrombospondin 1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis.
    Gwag T; Lee S; Li Z; Newcomb A; Otuagomah J; Weinman SA; Liang Y; Zhou C; Wang S
    JHEP Rep; 2024 Apr; 6(4):101019. PubMed ID: 38455470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression.
    Wang Q; Bu Q; Liu M; Zhang R; Gu J; Li L; Zhou J; Liang Y; Su W; Liu Z; Wang M; Lian Z; Lu L; Zhou H
    JHEP Rep; 2022 Nov; 4(11):100555. PubMed ID: 36185574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages.
    Drummer C; Saaoud F; Jhala NC; Cueto R; Sun Y; Xu K; Shao Y; Lu Y; Shen H; Yang L; Zhou Y; Yu J; Wu S; Snyder NW; Hu W; Zhuo J'; Zhong Y; Jiang X; Wang H; Yang X
    Front Immunol; 2023; 14():1113883. PubMed ID: 36776889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-specific deletion of thrombospondin 1 protects against inflammation and insulin resistance in long-term diet-induced obese male mice.
    Memetimin H; Li D; Tan K; Zhou C; Liang Y; Wu Y; Wang S
    Am J Physiol Endocrinol Metab; 2018 Dec; 315(6):E1194-E1203. PubMed ID: 30351986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.
    Engin A
    Adv Exp Med Biol; 2024; 1460():539-574. PubMed ID: 39287864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models.
    Gwag T; Ma E; Zhou C; Wang S
    Liver Int; 2022 Apr; 42(4):829-841. PubMed ID: 35129307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.
    Segal-Salto M; Barashi N; Katav A; Edelshtein V; Aharon A; Hashmueli S; George J; Maor Y; Pinzani M; Haberman D; Hall A; Friedman S; Mor A
    JHEP Rep; 2020 Feb; 2(1):100064. PubMed ID: 32039405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
    J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice.
    Yang L; Miura K; Zhang B; Matsushita H; Yang YM; Liang S; Song J; Roh YS; Seki E
    Cell Mol Gastroenterol Hepatol; 2017 May; 3(3):469-483. PubMed ID: 28462384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
    Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
    Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD.
    Oh S; Tsujimoto T; Kim B; Uchida F; Suzuki H; Iizumi S; Isobe T; Sakae T; Tanaka K; Shoda J
    JHEP Rep; 2021 Jun; 3(3):100253. PubMed ID: 33898958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.